Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir-Reference-Cited by-同舟云学术

Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir

Published:2023-09-11 Issue:7982 Volume:622 Page:376-382
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Duan Yinkai^ORCID,Zhou Hao,Liu Xiang^ORCID,Iketani Sho^ORCID,Lin Mengmeng^ORCID,Zhang Xiaoyu,Bian Qucheng,Wang Haofeng^ORCID,Sun Haoran,Hong Seo Jung,Culbertson Bruce^ORCID,Mohri Hiroshi^ORCID,Luck Maria I.,Zhu Yan,Liu Xiaoce,Lu Yuchi,Yang Xiuna^ORCID,Yang Kailin,Sabo Yosef^ORCID,Chavez Alejandro^ORCID,Goff Stephen P.^ORCID,Rao Zihe^ORCID,Ho David D.^ORCID,Yang Haitao^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

https://www.nature.com/articles/s41586-023-06609-0.pdf

Reference36 articles.

1. Owen, D. R. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586–1593 (2021).

2. Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. New Engl. J. Med. 386, 1397–1408 (2022).

3. Iketani, S. et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature https://doi.org/10.1038/s41586-022-05514-2 (2022).

4. Wang, Q. et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature https://doi.org/10.1038/s41586-022-05053-w (2022).

5. Wong, C. K. H. et al. Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: a retrospective cohort study. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(22)00507-2 (2022).

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patterned graphene: An effective platform for adsorption, immobilization, and destruction of SARS-CoV-2 Mpro;Journal of Colloid and Interface Science;2024-11

2. Highly specific SARS-CoV-2 main protease (Mpro) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system;Antiviral Research;2024-11

3. Identification of novel broad-spectrum antiviral drugs targeting the N-terminal domain of the FIPV nucleocapsid protein;International Journal of Biological Macromolecules;2024-11

4. A novel method for synthesizing authentic SARS-CoV-2 main protease;Protein Expression and Purification;2024-10

5. Discovery of Fluorescent Naturally‐Occurring Inhibitor of SARS‐CoV‐2 Main Protease by AIE Fluorescent Probe;ChemMedChem;2024-09-12